Related Experiment Video
Updated: Jan 10, 2026

Home-Based Monitor for Gait and Activity Analysis
Published on: August 8, 2019
Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient-Reported Measures
Maike Stein1,2,3,4, Haoqi Sun4, Sophie Lehnerer1,2,3
1Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background:
Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life-threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data.
Methods:
In this 12-week randomized controlled study, 30 MG patients recorded symptoms using patient-reported outcome measures (PROMs) and patient-performed measures via a mobile app, alongside data from wearables. MG deterioration was defined as a ≥ 3-point worsening in the Quantitative Myasthenia Gravis score, occurrence of MG-related hospitalization or exacerbation. A machine learning linear classifier was trained to predict deterioration and cross-validated. The area under the receiver operator characteristic curve (AUROC) was calculated, accepting 1-2 false alarms (FAs) per week.
Results:
The model achieved the best predictive performance when using all input signals (AUROC 0.85 (95% confidence interval 0.77-0.91)) and remained stable across look-back windows of 4-10 days. Model sensitivity was 0.65 (0.48-0.83) to 0.82 (0.60-1.00) (1 and 2 FAs per week, respectively). PROMs reflected worsening symptoms before deterioration; wearables alone showed higher AUROCs.
Interpretation:
Multimodal self-monitoring via MyaLink predicted MG deterioration with good performance at acceptable FA rates. This approach may enable earlier clinical interventions of MG worsening.
Trial Registration:
The study was registered under the German Clinical Trial Registry (DRKS00029907).
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

